For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
LPI (LP Information)' newest research report, the "Insulin API Industry Forecast" looks at past sales and reviews total world Insulin API sales in 2022, providing a comprehensive analysis by region and market sector of projected Insulin API sales for 2023 through 2029. With Insulin API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Insulin API industry.
This Insight Report provides a comprehensive analysis of the global Insulin API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Insulin API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Insulin API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Insulin API and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Insulin API.
The global Insulin API market size is projected to grow from US$ 1707.6 million in 2022 to US$ 2101.4 million in 2029; it is expected to grow at a CAGR of 2101.4 from 2023 to 2029.
The major players in global Insulin API market include Novo Nordisk, Sanofi-Aventis, etc. The top 2 players occupy over 65% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Insulin Analogue is the main market, and occupies about 90% of the global market. Long-Acting is the main type, with a share over 40%.
This report presents a comprehensive overview, market shares, and growth opportunities of Insulin API market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Regular Human Insulin
- Insulin Analogue
Segmentation by application
- Fast-Acting
- Premix
- Long-Acting
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Novo Nordisk
- Sanofi-Aventis
- Eli Lilly
- Tonghua Dongbao
- Ganlee
- United Laboratory
- Biocon
- Amphastar
- Wockhardt
- Julphar Diabetes
- Torrent Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Insulin API market?
What factors are driving Insulin API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Insulin API market opportunities vary by end market size?
How does Insulin API break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?